Enhanced safety and efficacy of live attenuated SIV vaccines by prevaccination with recombinant vaccines

The only vaccines shown to be protective against intravenous challenge with virulent virus in the simian immunodeficiency virus (SIV)/macaque model are attenuated live SIVs. However, these vaccines have several disadvantages: 1) they persist indefinitely in vaccinated macaques; 2) they are pathogenic to neonatal macaques; and 3) they are lethal in some adult macaques. To enhance the safety and efficacy of these vaccines, we immunized macaques first with recombinant vaccines and then inoculated the animals with SIVΔnef. In the first experiment, preimmunized macaques advanced to disease slower than controls after challenge with virulent SIV; five animals survived for 3 years without disease and only the vaccine virus (SIVΔnef) could be isolated at this time. In the second experiment, preimmunized animals had lower virus loads and no disease compared to controls.

[1]  H. McClure,et al.  Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques , 1999, Nature Medicine.

[2]  A. Osterhaus,et al.  Towards an HIV-1 vaccine: lessons from studies in macaque models. , 1998, Vaccine.

[3]  M. Robert-Guroff,et al.  An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge , 1997, Journal of virology.

[4]  R. Desrosiers,et al.  Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus , 1997, Journal of virology.

[5]  S. Ahmad,et al.  Expression of gamma interferon by simian immunodeficiency virus increases attenuation and reduces postchallenge virus load in vaccinated rhesus macaques , 1997, Journal of virology.

[6]  R. Desrosiers,et al.  Resistance of neonatal monkeys to live attenuated vaccine strains of simian immunodeficiency virus , 1997, Nature Medicine.

[7]  D. Montefiori,et al.  Vaccine protection by a triple deletion mutant of simian immunodeficiency virus , 1996, Journal of virology.

[8]  A. McMichael,et al.  Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques , 1995, Nature Genetics.

[9]  R. Bronson,et al.  Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. , 1995, Science.

[10]  L. Fabry,et al.  Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines , 1994, Journal of virology.

[11]  C. Scandella,et al.  Reduced virus load in rhesus macaques immunized with recombinant gp160 and challenged with simian immunodeficiency virus. , 1994, AIDS research and human retroviruses.

[12]  N. Haigwood,et al.  Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection , 1993, Journal of virology.

[13]  S. Ahmad,et al.  Immunological characterization of the VSV nucleocapsid (N) protein expressed by recombinant baculovirus in Spodoptera exigua larva: use in differential diagnosis between vaccinated and infected animals. , 1993, Virology.

[14]  R. Desrosiers,et al.  Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. , 1992, Science.

[15]  J. Playfair,et al.  The potential of cytokines as adjuvants. , 1992, AIDS research and human retroviruses.

[16]  P. Barr,et al.  Vaccinia virus recombinants expressing chimeric proteins of human immunodeficiency virus and gamma interferon are attenuated for nude mice. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[17]  N. Pedersen,et al.  Development of simian immunodeficiency virus isolation, titration, and neutralization assays which use whole blood from rhesus monkeys and an antigen capture enzyme-linked immunosorbent assay , 1991, Journal of clinical microbiology.

[18]  R. Desrosiers,et al.  Importance of the nef gene for maintenance of high virus loads and for development of AIDS , 1991, Cell.

[19]  G. Heidecker,et al.  Protection of macaques against simian AIDS by immunization with a recombinant vaccinia virus expressing the envelope glycoproteins of simian type D retrovirus. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[20]  I. N. Brown,et al.  Interferon-gamma as an adjuvant in immunocompromised mice. , 1989, Immunology.

[21]  T. Yilma,et al.  Enhancement of a secondary antibody response to vesicular stomatitis virus "G" protein by IFN-gamma treatment at primary immunization. , 1988, Journal of immunology.

[22]  T. Manser,et al.  Effect of IFN-gamma on the immune response in vivo and on gene expression in vitro. , 1984, Nature.